Illustration from Scientific Research

Estimated mean medium-term costs per patient with rifampin-susceptible tuberculosis treated with the standard of care (6 months of isoniazid, rifampin, pyrazinamide, and ethambutol for most patients) and with regimens meeting all optimal targets in the 2023 TRPs. TRP-optimal regimen costs include the costs of drugs when priced at their estimated medium-term cost-neutral prices (lightest blue), whereas standard-of-care regimen costs include the cost of drugs at their current prices (dark blue). The difference in the heights of the non-drug (non-lightest blue and non-dark blue) bars within each panel thus represent medium-term non-drug cost savings from an optimla TRP regimen. Shading indicates mean costs attributed to different components of treatment and error bars indicate uncertainty intervals (2·5th and 97·5th percentiles across 10 000 parameter set samples) for total cost estimates under the standard of care. The heights of the lightest blue bars (drug costs at cost-neutral prices) for the TRP-optimal regimens differ slightly from the thresholds shown intable 3(cost-neutral prices) because of wastage and incomplete person-time on treatment. Note the difference in y-axis scales between panels A and B. TRP=Target Regimen Profile.

DOI